As reported earlier, on March 18 the IPO Board of Directors adopted resolutions (1) supporting legislation affirmatively awarding fees and other expenses, in appropriate circumstances, to a prevailing party in patent cases, and (2) opposing the data disclosure policy of the European Medicines Agency. The full texts of the resolutions as adopted by the Board of Directors have now been posted on the IPO website.